Last reviewed · How we verify
NCT04336930: CAPPI
Evaluation of the "Pupillary Pain Index" in Neurological Prognosis After Cardiac Arrest
trial testing Pupillary pain index (PPI) in Cardiac Arrest in 60 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 November 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 1 July 2023 |
Drugs / interventions tested
- Pupillary pain index (PPI)
Conditions studied
- Cardiac Arrest — all drugs for Cardiac Arrest →
- Post-Anoxic Coma — all drugs for Post-Anoxic Coma →
- Anoxic Brain Injury — all drugs for Anoxic Brain Injury →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, any sex, with Cardiac Arrest or Post-Anoxic Coma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Two-thirds of patients admitted to the Intensive Care Unit after a cardiac arrest die in the context of treatment withdrawal after a multimodal evaluation that determines an unfavorable neurological outcome. This study will evaluate the Pupillary Pain Index (PPI) in the neurological prognosis after cardiac arrest. The PPI is determined by recording of pupillary dilatation with a videopupillometer after a calibrated and incremented nociceptive stimulus on a cutaneous metamere.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04336930
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Arrest
Currently open trials in the same condition.
- NCT07239206 — Serious Game for Improving Targeted Temperature Management Knowledge and Situational Awareness in Critical Care Nurses · NA · recruiting
- NCT06780722 — Study of the Occurrence of Cardiocirculatory Arrest as a Function of the Level of Hypoxemia During a Maastricht 3 Proced · recruiting
- NCT06405581 — The Impact of Frailty on Cardiopulmonary Resuscitation Adverse Outcomes in Patients Requiring Code Blue Activation · recruiting
- NCT06511999 — Continuous Jugular Venous Oxygen Saturation (SjO2) Measurement After Cardiac Arrest · recruiting
- NCT07113769 — Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation · recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04336930 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 24 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04336930.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing